Matched unrelated umbilical cord blood transplantation for a patient with chemotherapy resistant Wilms tumor

Kenneth G. Lucas, Terry Shapiro, Andrew Freiberg, Elizabeth Frauenhoffer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We report a patient with chemotherapy refractory Wilms tumor who underwent an unrelated donor cord blood transplant for chemotherapy refractory disease. The preparative regimen consisted of busulfan, melphalan, and anti-thymocyte globulin, and was well tolerated. This patient did not experience significant toxicity related to the chemotherapy regimen and did not develop any graft versus host disease from his HLA (A, B, DR) 6/6 matched cord blood transplant. Follow-up CT scans 2 years post-transplant have shown no evidence of disease progression, with only a few pulmonary nodules remaining, which are unchanged in size from his pre-transplant CT scan. It is possible that high-dose chemotherapy and stem cell transplantation can be curative in patients with tumors that are non-responsive to conventional chemotherapy. Pediatr Blood Cancer.

Original languageEnglish (US)
Pages (from-to)763-765
Number of pages3
JournalPediatric Blood and Cancer
Volume55
Issue number4
DOIs
StatePublished - Oct 1 2010

Fingerprint

Wilms Tumor
Fetal Blood
Transplantation
Drug Therapy
Transplants
Busulfan
Unrelated Donors
Melphalan
HLA-A Antigens
Antilymphocyte Serum
HLA-B Antigens
Stem Cell Transplantation
Graft vs Host Disease
Disease Progression
Neoplasms
Lung

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

@article{27a532a6c85c4b18a6efc3d679904caf,
title = "Matched unrelated umbilical cord blood transplantation for a patient with chemotherapy resistant Wilms tumor",
abstract = "We report a patient with chemotherapy refractory Wilms tumor who underwent an unrelated donor cord blood transplant for chemotherapy refractory disease. The preparative regimen consisted of busulfan, melphalan, and anti-thymocyte globulin, and was well tolerated. This patient did not experience significant toxicity related to the chemotherapy regimen and did not develop any graft versus host disease from his HLA (A, B, DR) 6/6 matched cord blood transplant. Follow-up CT scans 2 years post-transplant have shown no evidence of disease progression, with only a few pulmonary nodules remaining, which are unchanged in size from his pre-transplant CT scan. It is possible that high-dose chemotherapy and stem cell transplantation can be curative in patients with tumors that are non-responsive to conventional chemotherapy. Pediatr Blood Cancer.",
author = "Lucas, {Kenneth G.} and Terry Shapiro and Andrew Freiberg and Elizabeth Frauenhoffer",
year = "2010",
month = "10",
day = "1",
doi = "10.1002/pbc.22635",
language = "English (US)",
volume = "55",
pages = "763--765",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

Matched unrelated umbilical cord blood transplantation for a patient with chemotherapy resistant Wilms tumor. / Lucas, Kenneth G.; Shapiro, Terry; Freiberg, Andrew; Frauenhoffer, Elizabeth.

In: Pediatric Blood and Cancer, Vol. 55, No. 4, 01.10.2010, p. 763-765.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Matched unrelated umbilical cord blood transplantation for a patient with chemotherapy resistant Wilms tumor

AU - Lucas, Kenneth G.

AU - Shapiro, Terry

AU - Freiberg, Andrew

AU - Frauenhoffer, Elizabeth

PY - 2010/10/1

Y1 - 2010/10/1

N2 - We report a patient with chemotherapy refractory Wilms tumor who underwent an unrelated donor cord blood transplant for chemotherapy refractory disease. The preparative regimen consisted of busulfan, melphalan, and anti-thymocyte globulin, and was well tolerated. This patient did not experience significant toxicity related to the chemotherapy regimen and did not develop any graft versus host disease from his HLA (A, B, DR) 6/6 matched cord blood transplant. Follow-up CT scans 2 years post-transplant have shown no evidence of disease progression, with only a few pulmonary nodules remaining, which are unchanged in size from his pre-transplant CT scan. It is possible that high-dose chemotherapy and stem cell transplantation can be curative in patients with tumors that are non-responsive to conventional chemotherapy. Pediatr Blood Cancer.

AB - We report a patient with chemotherapy refractory Wilms tumor who underwent an unrelated donor cord blood transplant for chemotherapy refractory disease. The preparative regimen consisted of busulfan, melphalan, and anti-thymocyte globulin, and was well tolerated. This patient did not experience significant toxicity related to the chemotherapy regimen and did not develop any graft versus host disease from his HLA (A, B, DR) 6/6 matched cord blood transplant. Follow-up CT scans 2 years post-transplant have shown no evidence of disease progression, with only a few pulmonary nodules remaining, which are unchanged in size from his pre-transplant CT scan. It is possible that high-dose chemotherapy and stem cell transplantation can be curative in patients with tumors that are non-responsive to conventional chemotherapy. Pediatr Blood Cancer.

UR - http://www.scopus.com/inward/record.url?scp=77957068702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957068702&partnerID=8YFLogxK

U2 - 10.1002/pbc.22635

DO - 10.1002/pbc.22635

M3 - Article

C2 - 20589657

AN - SCOPUS:77957068702

VL - 55

SP - 763

EP - 765

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -